TheraRadar
← Back
Data updated: Nov 8, 2026

BIOCRYST

Pharma
ImmunologyOncologyOphthalmology Execution: Fair

BIOCRYST is a pharmaceutical company focused on Immunology, Oncology, Ophthalmology. Key products include RAPIVAB.

2014
Since
2
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
2 Small Molecules

FDA Novel Drug Designations

(2020)
1 Novel 1 Orphan 1 Fast Track
See 1 novel approval →
2020 ORLADEYO (BEROTRALSTAT DIHYDROCHLORIDE) Orphan · Fast Track

BIOCRYST at a Glance

  • Fast trial execution (13 months median completion)

BIOCRYST's Key Drugs

BIOCRYST's core commercial portfolio centers on RAPIVAB, ORLADEYO, spanning Immunology and Oncology — its most strategically important drugs approved in the last 15 years.

RAPIVAB
Infectious Disease

Influenza

Approved 2014
ORLADEYO
Rare Disease

Hereditary Angioedema

Plasma kallikrein Approved 2020

BIOCRYST's Recent FDA Approvals

BIOCRYST secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

ORLADEYO NDA
2025-12-11
berotralstat dihydrochloride
Hereditary Angioedema

BIOCRYST's Therapeutic Areas

BIOCRYST's approved drugs and pipeline span 4 therapeutic areas, led by Immunology and Oncology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 50%
0 drugs Phase 2: 2
Oncology 25%
0 drugs Phase 2: 1
Ophthalmology 13%
0 drugs Phase 1: 1
Infectious Disease 13%
0 drugs Phase 1: 1

BIOCRYST's Top Competitors

BIOCRYST's closest competitors by therapeutic-area and drug-target overlap include AbbVie, Pfizer, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

AbbVie big-pharma
Immunology, Oncology, Infectious Disease, Ophthalmology
Pfizer big-pharma
Oncology, Infectious Disease, Immunology
Novartis big-pharma
Oncology, Ophthalmology, Immunology
Baxter specialty
Infectious Disease, Oncology, Ophthalmology
Johnson & Johnson big-pharma
Oncology, Immunology, Infectious Disease

BIOCRYST Pipeline Snapshot

BIOCRYST has 5 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 3 Phase 2 and 2 Phase 1.

0
Phase 3
3
Phase 2
2
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • RAPIVAB leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Immunology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 5/11 completed
  • • Speed: 13 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges